Transplantation and Cellular Therapy Meetings | Conference

Dr Oluwole on CRS and Neurotoxicity Beyond 2 Weeks After Axi-Cel Infusion in R/R LBCL

February 17th 2025

Olalekan Oluwole, MD, MPH, discusses the incidence and resolution of CRS and neurological events beyond two weeks following axi-cel infusion in relapsed/refractory LBCL.

Dr Garfall on Ide-Cel and Lenalidomide Maintenance in Myeloma After Suboptimal ASCT Response

February 17th 2025

Alfred L. Garfall, MD, MS, discusses data for ide-cel and lenalidomide maintenance in multiple myeloma following a suboptimal response to ASCT and lenalidomide.

Ide-Cel Boosts Response in Myeloma With < CR After Upfront Auto-HCT and Lenalidomide Maintenance

February 16th 2025

Ide-cel proved feasible and effective in boosting response in patients with myeloma with suboptimal response to standard frontline therapy.

Non-Myeloablative HSCT Regimen Shows Potential for Immune Tolerance in Haploidentical Living Donor Combined Kidney/Hematopoietic Transplant

February 16th 2025

Non-myeloablative HSCT with TLI/TBI/ATG conditioning was safe and active in eliciting immune quiescence and tolerance.

FOXP3/Helios Expression in CD4+ Tcons Correlates With T-Cell Activation After Orca-T in Hematologic Malignancies

February 16th 2025

CD4-, FOXP3-, and Helios-positive conventional T cells were increased in patients receiving Orca-T vs peripheral blood stem cell grafts.

Drs Al Malki and Auletta on PTCy GVHD Prophylaxis in Patients With HLA-UUMD

February 15th 2025

Monzr Al Malki, MD and Jeffery J. Auletta, MD discuss evaluating PTCy-based GVHD prophylaxis in hematologic malignancies.

Orca-T’s Display of Decreased NRM, Increased RFS May Contribute to Favorable OS in Hematologic Malignancies

February 15th 2025

Orca-T improved OS vs post-transplant cyclophosphamide in a retrospective analysis of patients with hematologic malignancies.

Cilta-Cel Provides Deep MRD Negativity in Lenalidomide-Refractory Multiple Myeloma

February 15th 2025

Cilta-cel led to rapid and deep MRD negativity in patients with lenalidomide-refractory multiple myeloma.

Orca-Q Shows Promise in High-Risk Hematologic Cancers and BFT Conditioning May Synergize With the Agent

February 14th 2025

One-year follow-up data from an ongoing phase 1 study showed that Orca-Q offered similar benefits as T-cell depletion, without the typical compromises seen.

Obe-Cel Elicits High MRD-Negative Response Rates in R/R B-ALL

February 14th 2025

MRD-negative remissions with obe-cel were more durable and associated with higher EFS and OS rates vs MRD-positive remissions in relapsed/refractory B-ALL.

Axatilimab Displays Durable Responses in cGVHD Irrespective of Number of Prior Lines of Treatment

February 14th 2025

Axatilimab displayed similar efficacy regardless of the number of prior lines of therapy in chronic graft-versus-host disease.

Orca-T With RIC Is Safe in Advanced Hematologic Malignancies

February 14th 2025

Orca-T with reduced-intensity conditioning displayed robust and early donor myeloid and T-cell engraftment in advanced hematologic malignancies.

Ruxolitinib Plus SOC Prophylaxis Is Associated With Lower Rates of GVHD in Myelofibrosis

February 14th 2025

Ruxolitinib plus standard GVHD prophylaxis reduced GVHD in patients with myelofibrosis undergoing transplant.

Axatilimab, Ruxolitinib, and Belumosudil Combo Elicits Responses in Chronic GVHD

February 14th 2025

Favorable responses were demonstrated with the treatment of axatilimab plus ruxolitinib/belumosudil in heavily pretreated patients with chronic GVHD.

Dr Shah on Efficacy Data for Zamto-Cel in R/R DLBCL

February 14th 2025

Nirav Shah, MD, MSHP, discusses evaluating zamtocabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma

Dr Dholaria on the Safety and Efficacy of P-BCMA-ALLO1 in R/R Myeloma

February 14th 2025

Dr Dholaria discusses the phase 1 trial of P-BCMA-ALLO1, highlighting high response rates, rapid CAR T-cell expansion, and a favorable safety profile in RRMM.

Dr Ahmed on NKTR-255 With CD19-Directed CAR T-Cell Therapy in R/R LBCL

February 14th 2025

Sairah Ahmed, MD, discusses evaluating NKTR-255 in combination with CD19-directed CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma.

P-BCMA-ALLO1 Is Safe and Efficacious in R/R Multiple Myeloma

February 14th 2025

P-BCMA-ALLO1 displayed early efficacy and safety data in relapsed/refractory multiple myeloma.

Zamto-Cel Delivers Responses in R/R Diffuse Large B-Cell Lymphoma

February 14th 2025

Zamto-cel produced responses and was associated with low rates of CD19 and/or CD20 antigen loss in relapsed/refractory diffuse large B-cell lymphoma.

Anakinra Fails to Reduce CRS, ICANS Associated With Liso-Cel in LBCL

February 13th 2025

Anakinra did not reduce cytokine release syndrome or immune effector cell–associated neurotoxicity in patients with large B-cell lymphoma receiving liso-cel.